# Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

> **NCT01192724** · PHASE4 · COMPLETED · sponsor: **Yonsei University** · enrollment: 630 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Cilostazol
- **DRUG:** Aspirin
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT01192724
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2016-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192724, "Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01192724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*